Asaf Danziger serves as the CEO of NovoCure, a company focused on innovative cancer treatments. With an MBA from a respected business school, he’s been leading the company since January 2019. Danziger is known for having a big role in...
Asaf Danziger serves as the CEO of NovoCure, a company focused on innovative cancer treatments. With an MBA from a respected business school, he’s been leading the company since January 2019. Danziger is known for having a big role in helping the company aim to expand its oncology business and run vital clinical studies. Interestingly, he hasn’t received stock options or grants since 2021, showing a different approach in his compensation structure aiming to align his interests with senior management. In 2023, his total compensation was about $1.5 million, which included his salary and a substantial bonus tied to performance. His focus is on important corporate goals related to patients in clinical trials. Under his leadership, NovoCure has been working towards big achievements like obtaining FDA approvals for new treatments. Asaf was born in 1973 and brings a wealth of experience to the company, shaping it for future growth.